Facing the Hidden Flaws I See Every Project
I still remember a Monday in November 2023 at our Boston lab when a courier arrived with 20 fresh‑frozen biopsies for spatial transcriptomics; we lost five to low RNA integrity (RIN)—how could that have been prevented? Early reference to the sample requirements for spatial omics and the examples in the stereo-seq sample gallery changed our handling overnight. I write this as someone with over 15 years running lab operations and procurement for academic and commercial teams, and I mean it: small prep habits cascade into major failures (no joke).
Traditional fixes miss the real pain. Labs focus on a single metric—RIN or fixation time—while ignoring tissue thickness, ischemic interval, and the downstream library prep constraints that determine whether barcoding will work. I once pulled 10‑µm sections from archived FFPE blocks on a Friday and discovered the crosslinking had skewed library yields by 30% the next week; we reran two plates and burned three days of instrument time and roughly $4,200 in reagents. The practical details—knife angle, cryostat temperature, time on dry ice—matter more than vendor brochures suggest. We standardized sample labels, added digital timestamps to collection logs, and required a preflight photo for every slide. That cut our failed runs in half within two months.
Direct: Build Standards That Scale
What’s Next?
Clear sample rules save months and tens of thousands of dollars—period. When I advise teams now, I start from the checklist in the sample requirements for spatial omics and then tailor it to the assay: spatial transcriptomics needs controlled ischemic time and fresh‑frozen handling, while FFPE workflows tolerate longer storage but demand validated deparaffinization steps. Hold on. We also score vendors and internal collection sites on three concrete metrics before a pilot: sample integrity (RIN or equivalent), handling traceability (time‑stamped chain of custody), and compatibility with your library prep and barcoding scheme. These metrics are practical; they predict whether a run will succeed — and they let you compare suppliers apples to apples.
I speak from projects where a single change—enforcing 30‑minute max ischemic time at a hospital in Seattle—raised usable cell density by 18% in cortical tissue. That was in March 2022; we documented the difference, shared it with the clinical team, and the improvement stuck. Short pause. The forward path is simple: adopt tighter sample gates, require documented evidence (photos, timestamps), and choose reagents and instruments that match your intended throughput. Two quick interruptions here—this is not theoretical. It is operational, measurable.
To close, here are three evaluation metrics I use when choosing solutions: 1) Verified sample integrity score (quantitative RIN or equivalent, with threshold), 2) End‑to‑end traceability (photo + timestamp + chain‑of‑custody log), 3) Assay compatibility index (proof of successful library prep and barcoding on pilot samples). Use these to negotiate SLAs and to set acceptance criteria. I’ve applied them across university cores and midsize CROs; they work. For practical resources and real examples, see the gallery and standards at stomics.
0 Comments